VALIDATED EXECUTIVE ENGAGEMENTS
OUTREACH
3073
Number of executives repeatedly engaged by snail & email outreach
INTERACTIONS
554
Interactions with Platform & by Email
PARTICIPANTS
92
Unique # Participated
VALIDATIONS
41
Responses Validated*
* Login to view program details and full enterprise executive list.
DATE
JUL 2020
TABLES
104
PAGES
180
EDITION
6
PRICE
USD $4950
With the Global Economy Walking the Tightrope, It's the Numbers that Help Understand this Uncertain World.
Amid the COVID-19 crisis, the global market for Combination Antibody Therapy estimated at US$72.1 Billion in the year 2020, is projected to reach a revised size of US$173.4 Billion by 2027, growing at a CAGR of 13.4% over the analysis period 2020-2027. Chemotherapy/Antibody, one of the segments analyzed in the report, is projected to record a 9.6% CAGR and reach US$76.2 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Antibody/Antibody segment is readjusted to a revised 17.9% CAGR for the next 7-year period.
The Combination Antibody Therapy market in the U.S. is estimated at US$21.2 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$30.6 Billion by the year 2027 trailing a CAGR of 13% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 11.9% and 11.5% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 9.8% CAGR.
In the global Other Combinations segment, USA, Canada, Japan, China and Europe will drive the 12% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$3.8 Billion in the year 2020 will reach a projected size of US$8.5 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$21 Billion by the year 2027.We bring years of research experience to this 6th edition of our report. The 180-page report presents concise insights into how the pandemic has impacted production and the buy side for 2020 and 2021. A short-term phased recovery by key geography is also addressed.
Amgen, Inc.; Biogen, Inc.; Bristol-Myers Squibb Company; Celgene Corporation; Eli Lilly and Company; F. Hoffmann-La Roche AG; Genmab A/S; Novartis AG; Sanofi; Seattle Genetics, Inc.
» Application (Lung Cancer, Blood Cancer, Breast Cancer, Other Applications) » Combination (Chemotherapy/Antibody, Antibody/Antibody, Other Combinations) » End-Use (Hospitals, Cancer Research Institutes, Other End-Uses)
» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » and Rest of Europe » Asia-Pacific » Rest of World
INSIDER ACCESS PRIVILEGES
Users of our portal have insider access to our data stacks based on project relevance and engagement status. Tiered access is offered to data stacks, managed based on user status - Opt-in, Active Panelist, Inactive Panelist, Active Client or Inactive Client.
KEY DIFFERENTIATORS
We are firmly committed to build upon perspectives from global executive insights. These engagements enrich our projects. Our primary research programs are fully validated and accessible by clients. (Its a common industry-wide* practice that no validated primary research is done! For the most part, remote resident analysts curate and write reports drawing on search engine research and data modeling.
* A review of 262 off-the-shelf market report publishers worldwide.
WHAT SETS US APART
Client companies can access multiple features on our MarketGlass™ platform.
Clients have full-stack insider access to our ongoing primary research program. We have a very successful incentive driven primary research program that benefits participating executives regardless of their purchase decision. Our platform presents a unique opportunity to collaborate with peers and review competitors’ inputs and response clusters.
Detailed engagement stats are presented for every company and executive contacted. This is made available for our client reviews. (no other publisher offers this!)
A full-stack access to clients of all primary and secondary source content. This can often run into thousands of pages.
Where relevent and possible we present competitive brands.
Peer-to-peer online interactive collaborations. Allows for team curated bespoke analytics.
Customers can update and build bespoke versions of our analytics. Bespoke updates are fulfilled within a two-day turnaround.
Discretely bounce off queries to participant pool of executives. Our embedded AI selectively pings participants geographically and by domain acumen.
We pride in our commitment to provide support to our clients. We go beyond the scope of the study to get you timely answers.
Unlike the industry’s published PDF’s that are frozen in time from date of release, our research programs are ongoing and dynamic. Our reports are updated whenever there’s a major event impacting the marketplace. Your license offers seamless updates for one year.
All updates are offered for one year from date of your purchase without charge. Clients can opt for annual auto renewal and stay current without interruption.
05
| I. INTRODUCTION, METHODOLOGY & REPORT SCOPE |
| II. EXECUTIVE SUMMARY |
| 1. MARKET OVERVIEW |
| Global Competitor Market Shares |
| Combination Antibody Therapy Competitor Market Share Scenario Worldwide (in %): 2019 & 2025 |
| Impact of Covid-19 and a Looming Global Recession |
| 2. FOCUS ON SELECT PLAYERS |
| 3. MARKET TRENDS & DRIVERS |
| 4. GLOBAL MARKET PERSPECTIVE |
| Combination Antibody Therapy Global Market Estimates and Forecasts in US$ Million by Region/Country: 2020-2027 |
| Combination Antibody Therapy Market Share Shift across Key Geographies Worldwide: 2020 VS 2027 |
| Chemotherapy/Antibody (Combination) World Market by Region/Country in US$ Million: 2020 to 2027 |
| Chemotherapy/Antibody (Combination) Market Share Breakdown of Worldwide Sales by Region/Country: 2020 VS 2027 |
| Antibody/Antibody (Combination) Potential Growth Markets Worldwide in US$ Million: 2020 to 2027 |
| Antibody/Antibody (Combination) Market Sales Breakdown by Region/Country in Percentage: 2020 VS 2027 |
| Other Combinations (Combination) Geographic Market Spread Worldwide in US$ Million: 2020 to 2027 |
| Other Combinations (Combination) Market Share Distribution in Percentage by Region/Country: 2020 VS 2027 |
| Lung Cancer (Application) Demand Potential Worldwide in US$ Million by Region/Country: 2020-2027 |
| Lung Cancer (Application) Share Breakdown Review by Region/Country: 2020 VS 2027 |
| Blood Cancer (Application) Worldwide Latent Demand Forecasts in US$ Million by Region/Country: 2020-2027 |
| Blood Cancer (Application) Distribution of Global Sales by Region/Country: 2020 VS 2027 |
| Breast Cancer (Application) Sales Estimates and Forecasts in US$ Million by Region/Country for the Years 2020 through 2027 |
| Breast Cancer (Application) Global Market Share Distribution by Region/Country for 2020 and 2027 |
| Other Applications (Application) Global Opportunity Assessment in US$ Million by Region/Country: 2020-2027 |
| Other Applications (Application) Percentage Share Breakdown of Global Sales by Region/Country: 2020 VS 2027 |
| Hospitals (End-Use) Worldwide Sales in US$ Million by Region/Country: 2020-2027 |
| Hospitals (End-Use) Market Share Shift across Key Geographies: 2020 VS 2027 |
| Cancer Research Institutes (End-Use) Global Market Estimates & Forecasts in US$ Million by Region/Country: 2020-2027 |
| Cancer Research Institutes (End-Use) Market Share Breakdown by Region/Country: 2020 VS 2027 |
| Other End-Uses (End-Use) Demand Potential Worldwide in US$ Million by Region/Country: 2020-2027 |
| Other End-Uses (End-Use) Share Breakdown Review by Region/Country: 2020 VS 2027 |
| III. MARKET ANALYSIS |
| GEOGRAPHIC MARKET ANALYSIS |
| UNITED STATES |
| Market Facts & Figures |
| US Combination Antibody Therapy Market Share (in %) by Company: 2019 & 2025 |
| United States Combination Antibody Therapy Market Estimates and Projections in US$ Million by Combination: 2020 to 2027 |
| United States Combination Antibody Therapy Market Share Breakdown by Combination: 2020 VS 2027 |
| United States Combination Antibody Therapy Latent Demand Forecasts in US$ Million by Application: 2020 to 2027 |
| Combination Antibody Therapy Market Share Breakdown in the United States by Application: 2020 VS 2027 |
| United States Combination Antibody Therapy Latent Demand Forecasts in US$ Million by End-Use: 2020 to 2027 |
| Combination Antibody Therapy Market Share Breakdown in the United States by End-Use: 2020 VS 2027 |
| CANADA |
| Canadian Combination Antibody Therapy Market Estimates and Forecasts in US$ Million by Combination: 2020 to 2027 |
| Combination Antibody Therapy Market in Canada: Percentage Share Breakdown of Sales by Combination for 2020 and 2027 |
| Canadian Combination Antibody Therapy Market Quantitative Demand Analysis in US$ Million by Application: 2020 to 2027 |
| Canadian Combination Antibody Therapy Market Share Analysis by Application: 2020 VS 2027 |
| Canadian Combination Antibody Therapy Market Quantitative Demand Analysis in US$ Million by End-Use: 2020 to 2027 |
| Canadian Combination Antibody Therapy Market Share Analysis by End-Use: 2020 VS 2027 |
| JAPAN |
| Japanese Market for Combination Antibody Therapy: Annual Sales Estimates and Projections in US$ Million by Combination for the Period 2020-2027 |
| Japanese Combination Antibody Therapy Market Share Analysis by Combination: 2020 VS 2027 |
| Japanese Demand Estimates and Forecasts for Combination Antibody Therapy in US$ Million by Application: 2020 to 2027 |
| Combination Antibody Therapy Market Share Shift in Japan by Application: 2020 VS 2027 |
| Japanese Demand Estimates and Forecasts for Combination Antibody Therapy in US$ Million by End-Use: 2020 to 2027 |
| Combination Antibody Therapy Market Share Shift in Japan by End-Use: 2020 VS 2027 |
| CHINA |
| Chinese Combination Antibody Therapy Market Growth Prospects in US$ Million by Combination for the Period 2020-2027 |
| Chinese Combination Antibody Therapy Market by Combination: Percentage Breakdown of Sales for 2020 and 2027 |
| Chinese Demand for Combination Antibody Therapy in US$ Million by Application: 2020 to 2027 |
| Chinese Combination Antibody Therapy Market Share Breakdown by Application: 2020 VS 2027 |
| Chinese Demand for Combination Antibody Therapy in US$ Million by End-Use: 2020 to 2027 |
| Chinese Combination Antibody Therapy Market Share Breakdown by End-Use: 2020 VS 2027 |
| EUROPE |
| Market Facts & Figures |
| European Combination Antibody Therapy Market: Competitor Market Share Scenario (in %) for 2019 & 2025 |
| European Combination Antibody Therapy Market Demand Scenario in US$ Million by Region/Country: 2018-2025 |
| European Combination Antibody Therapy Market Share Shift by Region/Country: 2020 VS 2027 |
| European Combination Antibody Therapy Market Estimates and Forecasts in US$ Million by Combination: 2020-2027 |
| European Combination Antibody Therapy Market Share Breakdown by Combination: 2020 VS 2027 |
| European Combination Antibody Therapy Addressable Market Opportunity in US$ Million by Application: 2020-2027 |
| European Combination Antibody Therapy Market Share Analysis by Application: 2020 VS 2027 |
| European Combination Antibody Therapy Addressable Market Opportunity in US$ Million by End-Use: 2020-2027 |
| European Combination Antibody Therapy Market Share Analysis by End-Use: 2020 VS 2027 |
| FRANCE |
| Combination Antibody Therapy Market in France by Combination: Estimates and Projections in US$ Million for the Period 2020-2027 |
| French Combination Antibody Therapy Market Share Analysis by Combination: 2020 VS 2027 |
| Combination Antibody Therapy Quantitative Demand Analysis in France in US$ Million by Application: 2020-2027 |
| French Combination Antibody Therapy Market Share Analysis: A 7-Year Perspective by Application for 2020 and 2027 |
| Combination Antibody Therapy Quantitative Demand Analysis in France in US$ Million by End-Use: 2020-2027 |
| French Combination Antibody Therapy Market Share Analysis: A 7-Year Perspective by End-Use for 2020 and 2027 |
| GERMANY |
| Combination Antibody Therapy Market in Germany: Recent Past, Current and Future Analysis in US$ Million by Combination for the Period 2020-2027 |
| German Combination Antibody Therapy Market Share Breakdown by Combination: 2020 VS 2027 |
| Combination Antibody Therapy Market in Germany: Annual Sales Estimates and Forecasts in US$ Million by Application for the Period 2020-2027 |
| Combination Antibody Therapy Market Share Distribution in Germany by Application: 2020 VS 2027 |
| Combination Antibody Therapy Market in Germany: Annual Sales Estimates and Forecasts in US$ Million by End-Use for the Period 2020-2027 |
| Combination Antibody Therapy Market Share Distribution in Germany by End-Use: 2020 VS 2027 |
| ITALY |
| Italian Combination Antibody Therapy Market Growth Prospects in US$ Million by Combination for the Period 2020-2027 |
| Italian Combination Antibody Therapy Market by Combination: Percentage Breakdown of Sales for 2020 and 2027 |
| Italian Demand for Combination Antibody Therapy in US$ Million by Application: 2020 to 2027 |
| Italian Combination Antibody Therapy Market Share Breakdown by Application: 2020 VS 2027 |
| Italian Demand for Combination Antibody Therapy in US$ Million by End-Use: 2020 to 2027 |
| Italian Combination Antibody Therapy Market Share Breakdown by End-Use: 2020 VS 2027 |
| UNITED KINGDOM |
| United Kingdom Market for Combination Antibody Therapy: Annual Sales Estimates and Projections in US$ Million by Combination for the Period 2020-2027 |
| United Kingdom Combination Antibody Therapy Market Share Analysis by Combination: 2020 VS 2027 |
| United Kingdom Demand Estimates and Forecasts for Combination Antibody Therapy in US$ Million by Application: 2020 to 2027 |
| Combination Antibody Therapy Market Share Shift in the United Kingdom by Application: 2020 VS 2027 |
| United Kingdom Demand Estimates and Forecasts for Combination Antibody Therapy in US$ Million by End-Use: 2020 to 2027 |
| Combination Antibody Therapy Market Share Shift in the United Kingdom by End-Use: 2020 VS 2027 |
| REST OF EUROPE |
| Rest of Europe Combination Antibody Therapy Market Estimates and Forecasts in US$ Million by Combination: 2020-2027 |
| Rest of Europe Combination Antibody Therapy Market Share Breakdown by Combination: 2020 VS 2027 |
| Rest of Europe Combination Antibody Therapy Addressable Market Opportunity in US$ Million by Application: 2020-2027 |
| Rest of Europe Combination Antibody Therapy Market Share Analysis by Application: 2020 VS 2027 |
| Rest of Europe Combination Antibody Therapy Addressable Market Opportunity in US$ Million by End-Use: 2020-2027 |
| Rest of Europe Combination Antibody Therapy Market Share Analysis by End-Use: 2020 VS 2027 |
| ASIA-PACIFIC |
| Combination Antibody Therapy Market in Asia-Pacific by Combination: Estimates and Projections in US$ Million for the Period 2020-2027 |
| Asia-Pacific Combination Antibody Therapy Market Share Analysis by Combination: 2020 VS 2027 |
| Combination Antibody Therapy Quantitative Demand Analysis in Asia-Pacific in US$ Million by Application: 2020-2027 |
| Asia-Pacific Combination Antibody Therapy Market Share Analysis: A 7-Year Perspective by Application for 2020 and 2027 |
| Combination Antibody Therapy Quantitative Demand Analysis in Asia-Pacific in US$ Million by End-Use: 2020-2027 |
| Asia-Pacific Combination Antibody Therapy Market Share Analysis: A 7-Year Perspective by End-Use for 2020 and 2027 |
| REST OF WORLD |
| Rest of World Combination Antibody Therapy Market Estimates and Forecasts in US$ Million by Combination: 2020 to 2027 |
| Combination Antibody Therapy Market in Rest of World: Percentage Share Breakdown of Sales by Combination for 2020 and 2027 |
| Rest of World Combination Antibody Therapy Market Quantitative Demand Analysis in US$ Million by Application: 2020 to 2027 |
| Rest of World Combination Antibody Therapy Market Share Analysis by Application: 2020 VS 2027 |
| Rest of World Combination Antibody Therapy Market Quantitative Demand Analysis in US$ Million by End-Use: 2020 to 2027 |
| Rest of World Combination Antibody Therapy Market Share Analysis by End-Use: 2020 VS 2027 |
| IV. COMPETITION |
| Total Companies Profiled : 46 Click here to request a full table of contents and more details on this project. |
| V. CURATED RESEARCH |
INSIDER ACCESS TO
METHODOLOGY
QUESTIONNAIRE
INFLUENCER NETWORK
Registration is required to access our data stacks.
RESEARCH PANEL
Panelists are carefully chosen based on their domain expertise and market influence.
Participation in our expert panels is only by invitation. Our project focused panels are constituted of senior executives in business strategy, marketing, sales, and product management at competitive companies worldwide. We also welcome individuals from leading management consulting, venture capital, private equity, investment management and related firms with domain expertise and are actively monitoring specific companies or industries. Our panelists bring unique market perspectives and unbiased intelligence to our ongoing research programs.
Our panelists give 30-minutes a month or a one-time 30-minute participation based on their time and willingness.
- Complimentary previews of full stack research data for participated
- Insider access to research programs including engagements and stats from other panelists
- Unlimited research credits of $1000 per participated project
- Competitive Intelligence Alerts including engagements from other panelists and validated participants worldwide relevant to your company
- Interact with other panelists via our MarketGlassTM Data Exchange Platform*
- BlogX - Panelists can use our blogging platform publish their viewpoints on news relevant to their domain expertise. Platform enables panelists to share their viewpoints on current news and events related to their areas domain expertise with timely and insightful blogs*
* Complete details will be shared with panelists upon formal acceptance.
Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.
What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com